ArticleIranian journal of basic medical sciences2025
Repurposing Artrestan (Sacubitril/Valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats.
Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ulcerative colitis: from molecular pathophysiology to management and the emerging role of natural and pharmacological drug candidates.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Ulcerative colitis (UC) is an inflammatory disorder that is managed with various treatments, which have varying degrees of effectiveness and side effects, highlighting the need for new and more effective alternatives. In this study, we applied Artrestan (Sacubitrol/Valsartan), which has potent anti-inflammatory properties, alone or in combination with mesalazine, in the treatment of UC animal models. Materials and Methods: Thirty male rats were randomly divided into control, colitis, Artrestan (60 mg/kg/day), mesalazine (100 mg/kg/day), and Artrestan plus mesalazine groups. UC was induced by intrarectal administration of acetic acid, followed by a 5-day course of oral medication, during which the disease activity index (DAI), including diarrhea, weight loss, and rectal bleeding, was assessed daily. Macroscopic and microscopic examinations, as well as assessments of oxidant-anti-oxidant, pro-inflammatory, and pro-fibrotic factors, were performed on colonic tissue. Results: Administration of Artrestan, especially in combination with mesalazine, significantly decreased DAI and histological lesion scores in the microscopic assessment. Moreover, Artrestan modulated oxidant-anti-oxidant balance by increasing the activities of superoxide dismutase (SOD) and catalase (CAT) and reducing malondialdehyde (MDA) in colon tissue. Expression of inflammatory markers, including Interleukin 6 (IL-6) and Tumor necrosis factor-alpha (TNF-α), was decreased in the treated groups compared to the untreated group. Artrestan also attenuated fibrosis and collagen deposition in colon tissues, which was accompanied by a reduction in the expression of Transforming growth factor beta (TGF-β). Conclusion: Our findings suggest the therapeutic potential of Artrestan in combination with mesalazine for the treatment of UC, as it modulates clinical symptoms, improves the oxidant-anti-oxidant balance, and reduces pro-inflammatory and pro-fibrotic factors, supporting further investigations in the clinical phase.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.